Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain (Q34381226)

1 August 2017

title

Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain (English)

1 reference

1 August 2017

0 references

1 reference

Robert J Harvey

1

0 references

author name string

Benjamin K Yee

series ordinal

2

1 reference

1 August 2017

publication date

1 November 2013

1 reference

Nature Reviews Drug Discovery

1 August 2017

published in

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

11

1 reference

1 August 2017

page(s)

866-885

1 reference

Glycine receptor α2 subunit activation promotes cortical interneuron migration

1 August 2017

cites work

1 reference

NMDA receptor regulation by D-serine: new findings and perspectives

21 January 2018

1 reference

Glycine transporters: essential regulators of neurotransmission.

21 January 2018

1 reference

The genetics of hyperekplexia: more than startle!

21 January 2018

1 reference

Why glycine transporters have different stoichiometries.

21 January 2018

1 reference

The transporters GlyT2 and VIAAT cooperate to determine the vesicular glycinergic phenotype

21 January 2018

1 reference

Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition.

21 January 2018

1 reference

Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality

21 January 2018

1 reference

Glial glycine transporter 1 function is essential for early postnatal survival but dispensable in adult mice.

21 January 2018

1 reference

The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons

21 January 2018

1 reference

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

21 January 2018

1 reference

Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1

21 January 2018

1 reference

Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease

21 January 2018

1 reference

Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease

21 January 2018

1 reference

Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain

21 January 2018

1 reference

The scaffolding protein PSD-95 interacts with the glycine transporter GLYT1 and impairs its internalization

21 January 2018

1 reference

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions

21 January 2018

1 reference

NMDA receptor and schizophrenia: a brief history

21 January 2018

1 reference

Emerging opportunities for antipsychotic drug discovery in the postgenomic era.

21 January 2018

1 reference

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas

21 January 2018

1 reference

Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core

21 January 2018

1 reference

SLC6 neurotransmitter transporters: structure, function, and regulation

21 January 2018

1 reference

Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition

21 January 2018

1 reference

Gene knockout of glycine transporter 1: characterization of the behavioral phenotype

21 January 2018

1 reference

Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice

21 January 2018

1 reference

Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction

21 January 2018

1 reference

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

21 January 2018

1 reference

The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice

21 January 2018

1 reference

Neural substrates of latent inhibition: the switching model

21 January 2018

1 reference

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study

21 January 2018

1 reference

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia

21 January 2018

1 reference

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

21 January 2018

1 reference

Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour

21 January 2018

1 reference

2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic

21 January 2018

1 reference

Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers

21 January 2018

1 reference

Glycine receptors regulate dopamine release in the rat nucleus accumbens

21 January 2018

1 reference

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

21 January 2018

1 reference

The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice

21 January 2018

1 reference

Glycine transporter inhibition reverses ketamine-induced working memory deficits

21 January 2018

1 reference

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

21 January 2018

1 reference

Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).

21 January 2018

1 reference

Glycine-induced long-term synaptic potentiation is mediated by the glycine transporter GLYT1.

21 January 2018

1 reference

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels

21 January 2018

1 reference

Intact working memory in the absence of forebrain neuronal glycine transporter 1.

21 January 2018

1 reference

Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons

21 January 2018

1 reference

Examining the sex- and circadian dependency of a learning phenotype in mice with glycine transporter 1 deletion in two Pavlovian conditioning paradigms

21 January 2018

1 reference

D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats

21 January 2018

1 reference

Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?

21 January 2018

1 reference

Glycine binding primes NMDA receptor internalization

21 January 2018

1 reference

Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner.

21 January 2018

1 reference

Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice

21 January 2018

1 reference

Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice

21 January 2018

1 reference

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

21 January 2018

1 reference

The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats

21 January 2018

1 reference

Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor.

21 January 2018

1 reference

Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

21 January 2018

1 reference

The synthesis and preclinical evaluation in rhesus monkey of [18F]MK‐6577 and [11C]CMPyPB glycine transporter 1 positron emission tomography radiotracers

21 January 2018

1 reference

Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography

21 January 2018

1 reference

Inhibitors of GlyT1 affect glycine transport via discrete binding sites

21 January 2018

1 reference

Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists

21 January 2018

1 reference

Food and Drug Administration commentary on methodological issues in negative symptom trials

21 January 2018

1 reference

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

Glutamate signaling in the pathophysiology and therapy of schizophrenia

21 January 2018

1 reference

Glycine transport inhibitors and the treatment of schizophrenia

21 January 2018

1 reference

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

21 January 2018

1 reference

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

21 January 2018

1 reference

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

Glycine treatment of the risk syndrome for psychosis: report of two pilot studies

21 January 2018

1 reference

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

21 January 2018

1 reference

Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers

21 January 2018

1 reference

The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats

21 January 2018

1 reference

Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose

21 January 2018

1 reference

Glycine transporter-1 inhibition preceding extinction training inhibits reacquisition of cocaine seeking

21 January 2018

1 reference

Inhibiting glycine transporter-1 facilitates cocaine-cue extinction and attenuates reacquisition of cocaine-seeking behavior

21 January 2018

1 reference

Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats

21 January 2018

1 reference

The glycine reuptake inhibitor org 25935 interacts with basal and ethanol-induced dopamine release in rat nucleus accumbens

21 January 2018

1 reference

Involvement of accumbal glycine receptors in the regulation of voluntary ethanol intake in the rat.

21 January 2018

1 reference

Mechanisms for the modulation of native glycine receptor channels by ethanol

21 January 2018

1 reference

New pharmacological treatment strategies for relapse prevention

21 January 2018

1 reference

The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse

21 January 2018

1 reference

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene

21 January 2018

1 reference

An integrated genome research network for studying the genetics of alcohol addiction

21 January 2018

1 reference

The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.

21 January 2018

1 reference

The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect

21 January 2018

1 reference

Glutamatergic substrates of drug addiction and alcoholism

21 January 2018

1 reference

Cortico-Basal Ganglia reward network: microcircuitry

21 January 2018

1 reference

Glutamate receptors on dopamine neurons control the persistence of cocaine seeking.

21 January 2018

1 reference

Antidepressants in the treatment of neuropathic pain

21 January 2018

1 reference

Differential effects of the tricyclic antidepressant amoxapine on glycine uptake mediated by the recombinant GLYT1 and GLYT2 glycine transporters.

21 January 2018

1 reference

Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment

21 January 2018

1 reference

Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice

21 January 2018

1 reference

Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain

21 January 2018

1 reference

Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats

21 January 2018

1 reference

Intracerebroventricular or intrathecal injection of glycine produces analgesia in thermal nociception and chemical nociception via glycine receptors.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain

21 January 2018

1 reference

Administration of AP5, a glutamate antagonist, unmasks glycine analgesic actions in the rat

21 January 2018

1 reference

Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor

21 January 2018

1 reference

Increased hippocampal glycine uptake and cognitive dysfunction after peripheral nerve injury.

21 January 2018

1 reference

Lidocaine metabolites inhibit glycine transporter 1: a novel mechanism for the analgesic action of systemic lidocaine?

21 January 2018

1 reference

Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain.

21 January 2018

1 reference

The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model

21 January 2018

1 reference

Blockade of glycine transporter (GlyT) 2, but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain

21 January 2018

1 reference

Intrathecal glycine for pain and dystonia in complex regional pain syndrome.

21 January 2018

1 reference

Glycine transporter type-1 and its inhibitors.

21 January 2018

1 reference

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia

21 January 2018

1 reference

First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: relationship between exposure and dizziness.

21 January 2018

1 reference

Glycine transporter GLYT1 is essential for glycine-mediated protection of human intestinal epithelial cells against oxidative damage

21 January 2018

1 reference

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

21 January 2018

1 reference

21 January 2018

1 reference

When is polypharmacy an advantage?

21 January 2018

1 reference

Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence

21 January 2018

1 reference

Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors

21 January 2018

1 reference

Thinking outside the synapse: glycine at extrasynaptic NMDA receptors.

21 January 2018

1 reference

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

21 January 2018

1 reference

Pre-synaptic glycine GlyT1 transporter--NMDA receptor interaction: relevance to NMDA autoreceptor activation in the presence of Mg2+ ions

21 January 2018

1 reference

Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys

21 January 2018

1 reference

P2Y purinergic regulation of the glycine neurotransmitter transporters

21 January 2018

1 reference

The chromatin-binding protein HMGN3 stimulates histone acetylation and transcription across the Glyt1 gene

21 January 2018

1 reference

Nonketotic hyperglycinemia: a cause of encephalopathy in children.

21 January 2018

1 reference

Genetic heterogeneity of the GLDC gene in 28 unrelated patients with glycine encephalopathy.

21 January 2018

1 reference

Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia

21 January 2018

1 reference

Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia

21 January 2018

1 reference

GLRB is the third major gene of effect in hyperekplexia.

21 January 2018

1 reference

Novel missense mutations in the glycine receptor β subunit gene (GLRB) in startle disease

21 January 2018

1 reference

A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2

21 January 2018

1 reference

Highly effective SNP-based association mapping and management of recessive defects in livestock

21 January 2018

1 reference

Startle disease in Irish wolfhounds associated with a microdeletion in the glycine transporter GlyT2 gene

21 January 2018

1 reference

The inhibitory neural circuitry as target of antiepileptic drugs

21 January 2018

1 reference

Systemically administered glycine protects against strychnine convulsions, but not the behavioural effects of high pressure, in mice

21 January 2018

1 reference

Glycine potentiates the anticonvulsant action of diazepam and phenobarbital in kindled amygdaloid seizures of rats

21 January 2018

1 reference

Tonically active GABA A receptors: modulating gain and maintaining the tone.

21 January 2018

1 reference

Splice-specific roles of glycine receptor alpha3 in the hippocampus

21 January 2018

1 reference

Role of glycine receptors in glycine-induced LTD in hippocampal CA1 pyramidal neurons

21 January 2018

1 reference

Glycine uptake regulates hippocampal network activity via glycine receptor-mediated tonic inhibition

21 January 2018

1 reference

Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models

21 January 2018

1 reference

Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test

21 January 2018

1 reference

Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by D-serine and antagonized by 7-chlorokynurenic acid

21 January 2018

1 reference

The anticonvulsant activity of D-cycloserine is specific for tonic convulsions

21 January 2018

1 reference

Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice

21 January 2018

1 reference

Amino acid abnormalities in epileptogenic foci

21 January 2018

1 reference

7-Chlorokynurenic acid, a strychnine-insensitive glycine receptor antagonist, inhibits limbic seizure kindling

21 January 2018

1 reference

Activation of NMDA receptors blocks GABAergic inhibition in an in vitro model of epilepsy.

21 January 2018

1 reference

Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes

21 January 2018

1 reference

GRIN2A mutations cause epilepsy-aphasia spectrum disorders

21 January 2018

1 reference

Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes

21 January 2018

1 reference

GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction

21 January 2018

1 reference

Extrasynaptic and postsynaptic receptors in glycinergic and GABAergic neurotransmission: a division of labor?

21 January 2018

1 reference

State-dependent cross-inhibition between anionic GABA(A) and glycine ionotropic receptors in rat hippocampal CA1 neurons

21 January 2018

1 reference

Characterization of the inhibitory glycine receptor on entorhinal cortex neurons

21 January 2018

1 reference

Combining antiepileptic drugs--rational polytherapy?

21 January 2018

1 reference

Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults

21 January 2018

1 reference

Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study

21 January 2018

1 reference

On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions

21 January 2018

1 reference

The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder

21 January 2018

1 reference

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder

21 January 2018

1 reference

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

21 January 2018

1 reference

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

21 January 2018

1 reference

Effects of D-cycloserine on extinction: translation from preclinical to clinical work

21 January 2018

1 reference

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder

21 January 2018

1 reference

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

21 January 2018

1 reference

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

21 January 2018

1 reference

Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression

21 January 2018

1 reference

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

21 January 2018

1 reference

Glutamate system as target for development of novel antidepressants

21 January 2018

1 reference

A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice

21 January 2018

1 reference

Impacts of forebrain neuronal glycine transporter 1 disruption in the senescent brain: evidence for age-dependent phenotypes in Pavlovian learning

21 January 2018

1 reference

Adult brain neurogenesis and psychiatry: a novel theory of depression

21 January 2018

1 reference

GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization

21 January 2018

1 reference

Visceral, inflammatory and neuropathic pain in glycine receptor alpha 3-deficient mice

21 January 2018

1 reference

A Selective Role for alpha3 Subunit Glycine Receptors in Inflammatory Pain

21 January 2018

1 reference

Glycinergic mediation of tactile allodynia induced by platelet-activating factor (PAF) through glutamate-NO-cyclic GMP signalling in spinal cord in mice

21 January 2018

1 reference

Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.

21 January 2018

1 reference

Glycinergic neurons expressing enhanced green fluorescent protein in bacterial artificial chromosome transgenic mice

21 January 2018

1 reference

NMDA-type glutamate receptor is associated with cutaneous barrier homeostasis

21 January 2018

1 reference

Spinal prostaglandin E receptors of the EP2 subtype and the glycine receptor α3 subunit, which mediate central inflammatory hyperalgesia, do not contribute to pain after peripheral nerve injury or formalin injection

21 January 2018

1 reference

Glycine maintains excitement

21 January 2018

1 reference

Glycine transporters are differentially expressed among CNS cells.

21 January 2018

1 reference

The pharmacology of latent inhibition as an animal model of schizophrenia

31 March 2020

1 reference

A role for accumbal glycine receptors in modulation of dopamine release by the glycine transporter-1 inhibitor org25935.

31 March 2020

1 reference

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

31 March 2020

1 reference

31 March 2020

1 reference

Glycine therapy of schizophrenia: some caveats

31 March 2020

1 reference

Polypharmacy in Psychiatry Practice, Volume I

31 March 2020

1 reference

Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity

31 March 2020

1 reference

ATP binding to human serine racemase is cooperative and modulated by glycine

31 March 2020

1 reference

D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease

31 March 2020

1 reference

Glycine encephalopathy (nonketotic hyperglycinemia): comments and speculations

31 March 2020

1 reference

Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain.

31 March 2020

1 reference

Synergistic anticonvulsant effects of a GABA agonist and glycine

31 March 2020

1 reference

Glycine potentiates strychnine-induced convulsions: role of NMDA receptors

31 March 2020

1 reference

NMDA receptor activation enhances inhibitory GABAergic transmission onto hippocampal pyramidal neurons via presynaptic and postsynaptic mechanisms

31 March 2020

1 reference

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression

31 March 2020

1 reference

Molecular basis of the differential interaction with lithium of glycine transporters GLYT1 and GLYT2

31 March 2020

1 reference

ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter

31 March 2020

1 reference

12 December 2020

Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points

1 reference

12 December 2020

Atypical nonketotic hyperglycinemia with a defective glycine transport system in nervous tissue

1 reference

12 December 2020

Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex

1 reference

12 December 2020

Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

1 reference

12 December 2020

Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia

1 reference

12 December 2020

Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3893

1 reference

1 August 2017

1 reference